Prosecution Insights
Last updated: May 29, 2026

Asterias Biotherapeutics, Inc.

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
1
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (25%)
1
Medium (25%)
1
Easy (25%)
1
Unknown (25%)

Rejection Statute Mix

BucketCases
§101 only1 (25%)
§103 only1 (25%)
§112 only1 (25%)
No statute on record1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SMITH, ADAM MICHAEL 1
BERTOGLIO, VALARIE E 1 64.2% +29.6%
MOSS, NATALIE M 1 31.2% +17.2%
CONNORS, ALEXANDRA F 1 23.5% +44.0%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18262909 COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURIES SMITH, ADAM MICHAEL 22d overdue
16333566 PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY CONNORS, ALEXANDRA F 8d overdue

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18074272 DORSALLY-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS BERTOGLIO, VALARIE E 114d overdue
16333566 PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY CONNORS, ALEXANDRA F 8d overdue
17406074 PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY MOSS, NATALIE M 19d

Top Art Units

Art UnitApps
1638 1
1632 1
1653 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18262909 COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURIES SMITH, ADAM MICHAEL 1638 §101 Non-Final OA 22d overdue Pending Jul 25, 2023
18074272 DORSALLY-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS BERTOGLIO, VALARIE E 1632 §112 Final Rejection 114d overdue Pending Dec 02, 2022
17406074 PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY MOSS, NATALIE M 1653 Other Final Rejection 19d Pending Aug 18, 2021
16333566 PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF SPINAL CORD INJURY CONNORS, ALEXANDRA F 1634 §103 Final Rejection 8d overdue Pending Mar 14, 2019

Managing Asterias Biotherapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month